Fiche société
Ono Pharmaceutical Co., Ltd.
Traitements, essais et publications liés.
Traitements8programmes
Essais4liés
Publications0liées
SourceDBlocale
Traitements
8| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Cenobamate (syrup) for 2 to < 18 year oldsPrimary objective: To evaluate the safety and tolerability of cenobamate in Japanese pediatric subjects 2-17 years of age with partial-onset (focal) seizures | Épilepsie | Phase 3 | À vérifier | Japan | À vérifier |
| Cenobamate (tablet) for 12 to < 18 year oldsPrimary objective: To evaluate the safety and tolerability of cenobamate in Japanese pediatric subjects 2-17 years of age with partial-onset (focal) seizures | Épilepsie | Phase 3 | À vérifier | Japan | À vérifier |
| ONO-2020This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia. | Alzheimer | Phase 2 | À vérifier | United States, Japan | À vérifier |
| ONO-2506PODescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 2 | À vérifier | Belgium, France, Germany, Italy, Netherlands, Switzerland, United Kingdom | À vérifier |
| ONO-2506PODescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 2 | À vérifier | Belgium, France, Germany, Italy, Netherlands, Switzerland, United Kingdom | À vérifier |
| ONO-2020This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia. | Alzheimer | Phase 2 | À vérifier | United States, Japan | À vérifier |
| ONO-2020This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia. | Alzheimer | Phase 2 | À vérifier | Japan | À vérifier |
| Cenobamate (tablet) for 12 to < 18 year oldsPrimary objective: To evaluate the safety and tolerability of cenobamate in Japanese pediatric subjects 2-17 years of age with partial-onset (focal) seizures | Épilepsie | Phase 3 | À vérifier | Japan | À vérifier |
Essais cliniques
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Cenobamate (tablet) for 12 to < 18 year olds | Épilepsie | Phase 3 | NCT07594158 | A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds | RECRUITING |
| ONO-2020 | Alzheimer | Phase 2 | NCT06803823 | A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia | RECRUITING |
| ONO-2020 | Alzheimer | Phase 2 | NCT06881836 | A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease | COMPLETED |
| ONO-2506PO | Sclérose latérale amyotrophique | Phase 2 | NCT00694941 | A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS) | COMPLETED |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||